Skip to main content
News Tag: news
PI Perspective: The Journey of NRG-GY018
Read More
NRG Oncology and RTOG Foundation Integrated Efforts in the Head and Neck Cancer Committee
Read More
Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-positive Salivary Gland Cancer (NRG-HN010)
Read More
Webinar: Surgical Implications of ctDNA: Is this the future for colon cancer?
Read More
NRG Oncology Combined Trial Long-Term Results Indicate that Pathologic Complete Response is Prognostic of Outcomes for Soft Tissue Sarcoma Patients
Read More
Study Identifies Two Promising Molecular Targets for Drug Development in Recurrent and Metastatic Cervical Cancer
Read More
The Utilization of Atezolizumab as a Primer for Chemoradiation Results in Promising Immune System Alterations for Women with Locally Advanced Cervical Cancer
Read More
The Addition of Gemcitabine with Cisplatin and Intensity-Modulated Radiation Therapy Improves Outcomes for Women with Locally Advanced Vulvar Cancer
Read More
Circulating Tumor DNA: One of Our Newest Tools for Managing Solid Tumors
Read More
NRG-BR008 (“HERO”): A Phase III Randomized Trial Seeking to Optimize Use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer
Read More